The characteristic reaction after 6 h of treatment was the activation of “tumor-promoting inflammation”, such as IL-1 signaling with the up-regulation of IL1RAP and TOLLIP (Figure S17); IL-2 signaling with the up-regulation of IL2Rg and STAT5 (Figure S40); IL-6 signaling with the up-regulation of IL-6R, JAK2, and STAT3 (Figure S15); prostanoid biosynthesis with the up-regulation of prostaglandin E2 synthase (Figure S37); and TNFR2 signaling with the up-regulation of TNFR2 (Figure S6). The gene discussed is JAK2; the disease is neoplasm.